Full-Time

Associate Director / Director

Regulatory Affairs, CMC

Iambic Therapeutics

Iambic Therapeutics

51-200 employees

AI-driven discovery for oncology and neurology

Compensation Overview

$164k - $245k/yr

San Diego, CA, USA

Hybrid

Hybrid schedule based at the San Diego headquarters.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Microsoft Office
Biochemistry

Get referred to Iambic Therapeutics

See people who can refer or advise you

Requirements
  • A bachelor's degree in chemistry, biochemistry, pharmaceutical sciences, chemical engineering, or a related discipline is required.
  • Typically 8+ years of relevant pharmaceutical or biotechnology experience are required for Associate Director, or 10+ years for Director, including substantial CMC regulatory affairs experience.
  • Experience developing CMC regulatory strategy and preparing or reviewing Module 3/Quality content for clinical-stage submissions is required.
  • Ability to manage multiple programs and workstreams, establish priorities, maintain submission timelines, and deliver high-quality work in a fast-paced, dynamic, cross-functional environment is required.
  • Strong knowledge of global CMC requirements and guidance, including FDA and ICH expectations, is required.
  • Proficiency with regulatory document and submission tools, including regulatory information management, publishing and analysis tools, and Microsoft Office, is required.
Responsibilities
  • Develop and execute global CMC regulatory strategies for drug substance, drug product, analytical methods, manufacturing processes, controls, specifications, stability, packaging, and lifecycle activities.
  • Lead the planning, authoring, review, coordination, and timely delivery of CMC content for INDs, CTAs, amendments, annual reports, briefing packages, health authority responses, and other global filings.
  • Partner with Technical Operations, Process Chemistry, Analytical Development, Formulation, Manufacturing, Quality, Clinical, Nonclinical, Regulatory Operations, and external development and manufacturing organizations to ensure integrated CMC plans.
  • Provide regulatory guidance on phase-appropriate control strategies, comparability, specifications, stability, manufacturing changes, technology transfer, process validation, and later-stage readiness.
  • Represent Iambic in CMC-focused interactions with the US FDA and global health authorities, including meeting preparation, briefing materials, responses, and commitments.
  • Monitor global CMC regulations; identify CMC regulatory risks, gaps, and dependencies; develop mitigation strategies; and communicate intelligence, precedent, and potential impacts on program timelines, submission plans, and product development decisions.
  • Support due diligence, external partnerships, vendor oversight, and fit-for-purpose planning for CMC regulatory capabilities, systems, consultants, and headcount.
  • Develop and maintain relevant standard operating procedures and perform duties in alignment with company policies, quality systems, and applicable regulations.
Desired Qualifications
  • An advanced degree is preferred.
  • Small-molecule experience is preferred.

Iambic Therapeutics develops therapeutics using an AI-driven discovery platform, focusing on oncology and neurological diseases in clinical-stage programs. The platform combines advanced AI models with automated experiments to predict molecular properties faster and with less data, speeding identification and optimization of drug candidates. It differentiates itself by maintaining an in-house pipeline alongside strategic pharmaceutical partnerships to advance programs and earn milestones and royalties. The goal is to bring new therapies to patients by accelerating discovery and development through AI and automation.

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$303M

Headquarters

San Diego, California

Founded

2019

Get referred to Iambic Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Takeda’s February 2026 deal provides upfront, research, and technology-access payments.
  • Bayer joined June 2026, expanding non-dilutive validation beyond oncology into broader drug discovery.
  • Iambic raised over $100 million in November 2025, supporting runway into 2028.

What critics are saying

  • Takeda’s billion-dollar value depends on milestones; failure in programs kills economics.
  • IAM1363 remains single-asset clinical proof; Phase 1b setbacks would crush credibility.
  • Big pharma can internalize AI discovery, and Bayer or Takeda can switch vendors.

What makes Iambic Therapeutics unique

  • NeuralPLexer and Enchant anchor Iambic’s AI stack for structure and endpoint prediction.
  • Takeda chose Iambic in February 2026, validating platform value with blue-chip pharma.
  • IAM1363 reached Phase 1/1b in two years, versus six-year industry averages.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Company Match

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-2%
Intelligence360 News
Dec 3rd, 2025
Iambic Therapeutics raises $125M in new funding

Iambic Therapeutics has filed a notice with the US Securities and Exchange Commission for an exempt offering to raise $125 million in new funding. The filing was made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act, which allows companies to sell securities without registration under the Securities Act of 1933. Federal securities law requires such notices to be filed within 15 days after the first sale of securities in the offering. No additional details about the funding round, including investors or valuation, were disclosed in the filing.

Iambic Therapeutics
Nov 11th, 2025
Iambic Raises Over $100 Million in an Oversubscribed Round to Advance its Portfolio of AI-Discovered Therapeutics and Leading Platform Technologies

San Diego, CA – Nov. 10, 2025 – Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced raising over $100 million in an oversubscribed financing round with balanced support from new and existing investors, including Abingworth, Alexandria Venture Investments, Alumni Ventures, ARK, Ascenta, Catalio, Everbright Biofund, Freeflow Ventures, Illumina Ventures, Mubadala, Pegasus Tech Ventures, Qatar Investment Authority, Regeneron Ventures, Sequoia, Tao Capital Partners, Terra Magnum Capital Partners, Wilson Sonsini Goodrich & Rosati, and others.

Endpoints News
Nov 10th, 2025
Iambic Therapeutics raises $100M funding

Iambic Therapeutics has secured over $100 million in a new funding round, as revealed by CEO Tom Miller. The investment comes from ARK and Regeneron, highlighting significant financial backing for the San Diego-based biotech company.

EntArabi
Jun 20th, 2024
Iambic Therapeutics raises $50M in Series B

Iambic Therapeutics, a US-based biotech company, raised $50 million in an expanded Series B funding round led by Mubadala Capital. The round included Qatar Investment Authority, Exor Ventures, and existing investors like Abingworth, Illumina Ventures, Nexus Venture Partners, Coatue, and Tao Capital Partners. This funding is part of a previous $100 million Series B round closed in October 2023. The funds will be used to advance Iambic's clinical and preclinical programs.

Pharmaceutical Business Review
Jun 19th, 2024
Iambic secures $50m to bolster clinical oncology programme pipeline

Iambic Therapeutics has secured $50m in its Series B extension financing round to bolster its pipeline comprising clinical oncology programmes.